162 results
Page 5 of 9
6-K
EX-99.1
mf4vz2h6
8 Mar 21
Enlivex Receives Notice of Allowance for Japanese Patent Application
8:03am
6-K
EX-99.1
g6fxxf230if3lda46j
1 Mar 21
Report of Foreign Private Issuer
7:58am
6-K
EX-99.1
fn5cs
22 Feb 21
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy
8:04am
6-K
EX-99.1
45i3ot555yxgl9r
18 Feb 21
Enlivex Announces Exercise of Underwriter’s Option to Purchase Additional Shares
8:03am
6-K
EX-99.1
pzgnuenz01drwvx
16 Feb 21
Current report (foreign)
8:30am
6-K
EX-1.1
v4xupga
12 Feb 21
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
5:17pm
6-K
EX-99.1
z1eiquuwq5d
12 Feb 21
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
5:17pm
424B5
11r8bm d1emjxo
10 Feb 21
Prospectus supplement for primary offering
5:22pm
FWP
x3h6hud6 f7x4e
10 Feb 21
Free writing prospectus
6:08am
FWP
pnl5un 87xhvwjhdyi
9 Feb 21
Free writing prospectus
5:21pm
424B5
k5zokrhz 4ew3xegm
9 Feb 21
Prospectus supplement for primary offering
4:56pm
6-K
EX-99.1
qqj1rzs
3 Feb 21
Current Report
7:55am
6-K
prgpz 83y
21 Dec 20
Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv
8:02am
6-K
EX-99.1
wjkyzuv03
21 Dec 20
Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv
8:02am
6-K
EX-99.1
vfwfoakj25q
7 Dec 20
Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy
8:02am
6-K
EX-99.1
c9g7lasozgakxh2ieakw
3 Dec 20
Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
8:00am
6-K
EX-99.1
qa1jhkivlpxw 00t045
18 Nov 20
Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra
8:02am
6-K
EX-99.1
93cokw 00dd
17 Nov 20
Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company’s Board of Directors
8:18am
6-K
EX-99.1
2pu94u
12 Nov 20
Enlivex to Present Schedule for Sepsis, COVID-19 and Solid Cancer Programs at H.C. Wainwright’s 6th Annual Israel Conference
8:01am
6-K
EX-99.1
xzcyvl99
3 Nov 20
Current report (foreign)
9:14am